%0 Journal Article
%T Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial
%A Aharon Erez
%A Alexander Tenenbaum
%A Enrique Z. Fisman
%A Ilan Goldenberg
%A Nir Shlomo
%A Robert Klempfner
%A Sagit Benzekry
%A Yaron Arbel
%A for the BIP Study Group
%J Archive of "Cardiovascular Diabetology".
%D 2016
%R 10.1186/s12933-016-0332-6
%X Recent data support the renewed interest in hypertriglyceridemia as a possible important therapeutic target for cardiovascular risk reduction. This study was designed to address the question of all-cause mortality during extended follow-up of the BIP trial in patients stratified by baseline triglyceride levels
%K Bezafibrate
%K Triglycerides
%K Coronary disease
%K Prognosis
%K Mortality
%K Lipids
%K Cholesterol
%K HDL
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722704/